Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Match Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Match Group Inc trades at $36.82 (market cap $8.43B). The key difference: Match Group Inc is the larger of the two by market cap, and Match Group Inc pays a 2.18% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MTCH | |
|---|---|---|
Market Cap | $5.06B | $8.43B |
Sector | Health | Media |
52-Week High | $29.39 | $41.24 |
52-Week Low | $20.06 | $28.90 |
Enterprise Value | $4.18B | $11.40B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
MTCH trades at $37.26, up 1.78% on the day, with a bearish technical signal and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 EPS estimates but missing on revenue, as Tinder faces headwinds while Hinge grows. Strong profitability is evident with a 74.8% gross margin and 20.17% net income margin, though high debt levels remain a concern. Recent news highlights institutional buying interest amid ongoing business transformation.
The outlook is cautiously optimistic, supported by a consensus price target of $42.33 (13.6% upside) and no sell ratings. Key opportunities include Hinge's international expansion and Tinder's turnaround potential, but risks involve execution challenges, competitive pressures, and significant leverage. Earnings growth remains the primary catalyst for valuation re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
